Celebrated today at the General Assembly of the Organisation of European Cancer Institutes (OECI), VHIO’s Director and Head of the Vall d’Hebron University Hospital’s Medical Oncology Department, Josep Tabernero, has been appointed as a member of its Board of Directors.
Since June 2023, the Vall d’Hebron Hospital Campus has been accredited by OECI as a Comprehensive Cancer Center through its Accreditation and Designation (A&D) Programme achieve this level of accreditation*. This prestigious award recognizes multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Institute of Oncology (VHIO), and Vall d’Hebron Research Institute (VHIR).
“I am truly honored to serve OECI as member of its Executive Board. Alongside OECI’s esteemed Board Members, and in collaboration with its dedicated Working Groups, I am equally committed to ensuring equitable access to multidisciplinary and personalized cancer care of excellence to all patients, and reducing the burden of this disease,” says Josep Tabernero.
“To do so, we must all continue to deliver on OECI’s mission. Namely, to work together to promote and enhance the concept of comprehensiveness and multi-disciplinarity, support quality in cancer care, dynamically work in crosscutting expertise, and promote synergies with other cancer organizations,” concludes Tabernero.
—
*Following an exhaustive external evaluation, having successfully complied with 85 standards and 342 sub-standards—both qualitative and quantitative—Vall d’Hebron is the first to receive this level of accreditation in Spain.
###
About OECI
The OECI is a non-governmental Organisation founded in Vienna in 1979 and remodelled in 2005 into OECI-EEIG, an European Economic Interest Grouping. OECI presently comprises 123 Members, which include some of the most prominent European Comprehensive Cancer Centres.
The OECI aim is to accelerate the application of multidisciplinary personalised care approaches to reduce mortality and to guarantee an equitable access to care to all cancer patients and supporting parallel initiatives outside the EU and in other continents.
